Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
681 | 3098 | 48.6 | 93% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
40 | 31853 | AIDS RESEARCH AND HUMAN RETROVIRUSES//HIV 1//AIDS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PARTNERS AIDS | Address | 92 | 41% | 6% | 172 |
2 | HIV PATHOGENESIS PROGRAMME | Address | 36 | 44% | 2% | 61 |
3 | DORIS DUKE MED | Address | 34 | 36% | 2% | 75 |
4 | ESCI GRP | Address | 28 | 68% | 1% | 25 |
5 | ELITE CONTROLLERS | Author keyword | 27 | 59% | 1% | 30 |
6 | HUMAN IMMUNOL UNIT | Address | 20 | 22% | 3% | 81 |
7 | CYTOTOXIC T LYMPHOCYTE ESCAPE | Author keyword | 17 | 100% | 0% | 8 |
8 | HIV PATHOGENESIS PROGRAM | Address | 16 | 64% | 1% | 16 |
9 | HIV VACCINE | Author keyword | 16 | 24% | 2% | 57 |
10 | RAGON | Address | 13 | 21% | 2% | 57 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ELITE CONTROLLERS | 27 | 59% | 1% | 30 | Search ELITE+CONTROLLERS | Search ELITE+CONTROLLERS |
2 | CYTOTOXIC T LYMPHOCYTE ESCAPE | 17 | 100% | 0% | 8 | Search CYTOTOXIC+T+LYMPHOCYTE+ESCAPE | Search CYTOTOXIC+T+LYMPHOCYTE+ESCAPE |
3 | HIV VACCINE | 16 | 24% | 2% | 57 | Search HIV+VACCINE | Search HIV+VACCINE |
4 | ELITE CONTROL | 11 | 78% | 0% | 7 | Search ELITE+CONTROL | Search ELITE+CONTROL |
5 | SIV | 8 | 10% | 2% | 73 | Search SIV | Search SIV |
6 | HIV CONTROLLERS | 8 | 50% | 0% | 11 | Search HIV+CONTROLLERS | Search HIV+CONTROLLERS |
7 | SUBDOMINANT EPITOPES | 6 | 80% | 0% | 4 | Search SUBDOMINANT+EPITOPES | Search SUBDOMINANT+EPITOPES |
8 | HIV 1 VACCINE | 6 | 26% | 1% | 19 | Search HIV+1+VACCINE | Search HIV+1+VACCINE |
9 | CANARYPOX | 5 | 45% | 0% | 9 | Search CANARYPOX | Search CANARYPOX |
10 | CROSS CLADE | 5 | 63% | 0% | 5 | Search CROSS+CLADE | Search CROSS+CLADE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | LONG TERM NONPROGRESSORS | 119 | 51% | 5% | 166 |
2 | VIRAL ESCAPE | 102 | 67% | 3% | 92 |
3 | VIREMIA | 97 | 19% | 15% | 457 |
4 | LYMPHOCYTE ESCAPE | 90 | 83% | 2% | 50 |
5 | ESCAPE MUTATIONS | 87 | 64% | 3% | 86 |
6 | IMMUNE CONTROL | 86 | 62% | 3% | 90 |
7 | LYMPHOCYTE RESPONSES | 67 | 25% | 8% | 238 |
8 | AIDS VACCINE | 61 | 39% | 4% | 123 |
9 | ELITE CONTROLLERS | 60 | 63% | 2% | 61 |
10 | CELL RESPONSES | 56 | 19% | 9% | 264 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Impact of MHC class I diversity on immune control of immunodeficiency virus replication | 2008 | 222 | 105 | 86% |
HIV-1 adaptation to HLA: a window into virus-host immune interactions | 2015 | 2 | 112 | 81% |
HIV and HLA Class I: An Evolving Relationship | 2012 | 51 | 119 | 84% |
The immune response during acute HIV-1 infection: clues for vaccine development | 2010 | 259 | 154 | 34% |
HIV and SIVCTL escape: Implications for vaccine design | 2004 | 317 | 86 | 76% |
Human immunodeficiency virus controllers: Mechanisms of durable virus control in the absence of antiretroviral therapy | 2007 | 286 | 91 | 47% |
Toward an AIDS vaccine | 2008 | 204 | 44 | 50% |
Unravelling the mechanisms of durable control of HIV-1 | 2013 | 26 | 130 | 62% |
CD8(+) T cells in preventing HIV infection and disease | 2012 | 32 | 173 | 72% |
Success and failure of the cellular immune response against HIV-1 | 2015 | 1 | 111 | 80% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PARTNERS AIDS | 92 | 41% | 5.6% | 172 |
2 | HIV PATHOGENESIS PROGRAMME | 36 | 44% | 2.0% | 61 |
3 | DORIS DUKE MED | 34 | 36% | 2.4% | 75 |
4 | ESCI GRP | 28 | 68% | 0.8% | 25 |
5 | HUMAN IMMUNOL UNIT | 20 | 22% | 2.6% | 81 |
6 | HIV PATHOGENESIS PROGRAM | 16 | 64% | 0.5% | 16 |
7 | RAGON | 13 | 21% | 1.8% | 57 |
8 | HUMAN RETROVIRUS PATHOGENESIS SECT | 10 | 33% | 0.8% | 25 |
9 | WISCONSIN PRIMATE | 10 | 16% | 1.8% | 57 |
10 | AIDS IMMUNOPATHOGENESIS | 9 | 41% | 0.6% | 18 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000185836 | HGP 30//VACCINE DEV BRANCH//HIV 1 IMMUNOGEN |
2 | 0.0000128216 | SIV//SHIV//SIMIAN IMMUNODEFICIENCY VIRUS |
3 | 0.0000110223 | IAVI NEUTRALIZING ANTIBODY//DUKE HUMAN VACCINE//HIV AIDS VACCINE IMMUNOL IMMUNOGEN DISCOVER |
4 | 0.0000110026 | UNITE RETROVIROL MOL//ENTROPY EVOLUTION RATE//HIV 1 MOTHER TO CHILD TRANSMISSION |
5 | 0.0000106576 | EXPOSED UNINFECTED//HESN//IMMUNOBIOL HIV UNIT |
6 | 0.0000097445 | HIV LATENCY//HIV CURE//HIV 1 LATENCY |
7 | 0.0000092442 | IMMUNE RECONSTITUTION//CLIN MOL RETROVIROL SECT//IMMUNE ACTIVATION |
8 | 0.0000087415 | IMMUNOINFORMATICS//EPITOPE PREDICTION//COMPUTATIONAL VACCINOLOGY |
9 | 0.0000083785 | DNA VACCINE//DNA VACCINES//DNA IMMUNIZATION |
10 | 0.0000081424 | CMV SPECIFIC T CELLS//ONCOHEMATOL GRP//CYTOMEGALOVIRUS SPECIFIC T CELLS |